Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -87.1%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $128262 | $2M | $304241 | $180015 | $220170 | $652365 | $3M | — | — | — |
| Enterprise Value | $-4016738 | $-2065007 | $-3911759 | $-7759985 | $-3875830 | $-15884635 | $-13059368 | — | — | — |
| P/E Ratio → | -0.20 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 7.54 | 122.35 | — | — | 2.56 | — | — | — | — | — |
| P/B Ratio | 0.11 | 0.22 | 0.17 | 0.02 | 0.02 | 0.04 | 0.16 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -121.47 | — | — | -45.07 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -4864.7% | -4864.7% | — | — | 82.6% | — | — | — | — | — |
| Operating Margin | -29335.3% | -29335.3% | — | — | -10312.8% | — | — | — | — | — |
| Net Profit Margin | -28458.8% | -28458.8% | — | — | -10223.3% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -87.1% | -87.1% | -321.9% | -102.3% | -60.4% | -41.8% | -73.7% | — | — | — |
| ROA | -58.6% | -58.6% | -201.8% | -84.0% | -56.0% | -39.3% | -42.7% | -292.4% | -561.4% | -976.6% |
| ROIC | -271.7% | -271.7% | — | -231.0% | -157.1% | -434.6% | -453.3% | — | -1630.4% | — |
| ROCE | -85.7% | -85.7% | -305.6% | -102.0% | -60.0% | -41.0% | -28.6% | — | -704.2% | -1113.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.02 | 0.01 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.45 | -2.31 | -1.10 | -0.37 | -0.91 | -0.94 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -498.70 | -498.70 | -1040.43 | -24.96 | -143.77 | -723.00 | -1.69 | -1.27 | -1.55 | — |
Net cash position: cash ($4M) exceeds total debt ($21000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.78 | 1.78 | 1.81 | 4.07 | 11.55 | 25.13 | 18.51 | 0.15 | 4.44 | 1.58 |
| Quick Ratio | 1.78 | 1.78 | 1.81 | 4.07 | 4.19 | 25.13 | 16.39 | 0.15 | 4.44 | 1.58 |
| Cash Ratio | 1.71 | 1.71 | 1.74 | 3.33 | 3.85 | 21.85 | 16.31 | 0.15 | 2.22 | 1.39 |
| Asset Turnover | — | 0.00 | — | — | 0.01 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | 0.00 | — | — | — | — | — |
| Days Sales Outstanding | — | 3048.82 | — | — | 233.43 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $647973 | $18142 | $2182 | $1777 | $1635 | $1952 | $1551 | $2306 | $2306 |
Imminent liquidity and dilution
According to current market data, PRFX trades at a price-to-sales ratio of 7.54, a figure that appears disconnected from operational reality given the company's lack of commercial revenue and the binary nature of its ongoing Phase 3 clinical trials for the PRF-110 delivery platform.
The elevated P/S multiple reflects investor speculation on the potential for future licensing or acquisition rather than any underlying fundamental performance. Investors should monitor this valuation closely, as it remains highly sensitive to clinical trial enrollment velocity and the company's ability to secure non-dilutive funding.
Based on reported financial statements, PRFX has consistently generated negative returns on invested capital, with ROIC figures reaching -17.7% in 2025Q2, illustrating the company's ongoing struggle to deploy capital efficiently while remaining in a pre-revenue, high-burn clinical development phase.
The decay in ROIC is a direct consequence of sustained R&D expenditures without a corresponding revenue stream to offset the cost of capital. This trend suggests that until the company achieves regulatory approval and commercialization, capital efficiency will remain structurally impaired compared to established specialty pharmaceutical peers.
As indicated by the most recent quarterly filings, the current ratio has compressed to 1.59, a significant decline from the 9.81 level observed in 2023Q3, signaling that the company's liquidity position is rapidly deteriorating as it funds late-stage clinical trials with limited cash reserves.
The rapid depletion of the current ratio suggests that the company's ability to meet short-term obligations is becoming increasingly constrained. Without a successful capital raise or strategic partnership, the current liquidity profile appears insufficient to support the full duration of the ongoing Phase 3 clinical programs.
Analysts frequently misapply traditional profitability metrics like net margin to PRFX, which obscures the company's true financial status as a pre-revenue biotech entity where negative margins are a structural feature of the R&D-heavy business model rather than an indicator of operational failure.
Focusing on net margins in this context is misleading because it ignores the necessary investment in clinical de-risking that defines the firm's current lifecycle stage. Instead, investors should prioritize the 'Cash Runway-to-Data Readout' metric to better assess the company's survival probability and potential for future value creation.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRFX stock.
PRF Technologies Ltd.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
PRF Technologies Ltd.'s return on equity (ROE) is -87.1%. The historical average is -114.5%.
Based on historical data, PRF Technologies Ltd. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
PRF Technologies Ltd. has -4864.7% gross margin and -29335.3% operating margin.